Motavizumab was shown to reduce hospitalizations in Native American infants due to respiratory syncytial virus (RSV) by 83% as compared to placebo, according to Phase 3 study results announced by MedImmune Inc.
- Efficacy — Motavizumab reduced RSV-related hospital admissions by 87% in healthy term Native American infants compared with placebo, showing strong protection against severe RSV disease.
- Safety — Serious adverse events were less common with motavizumab than placebo, though hypersensitivity reactions were slightly more frequent, and deaths were rare and unrelated to treatment.
- Long-Term Outcomes — Motavizumab did not reduce medically attended wheezing in children aged 1–3 years, suggesting RSV infection in infancy is not a direct cause of later wheezing.
